Shin H, Kim H, Kwon S, Lee H, Lee J, Kim Y
Mol Cells. 2025; 48(2):100175.
PMID: 39743142
PMC: 11873615.
DOI: 10.1016/j.mocell.2024.100175.
Yosri M, Dokhan M, Aboagye E, Moussawy M, Abdelsamed H
Front Immunol. 2024; 15:1465889.
PMID: 39669576
PMC: 11635090.
DOI: 10.3389/fimmu.2024.1465889.
Russell J, Chen L, Liu A, Wang J, Ghosh S, Zhong X
EMBO Rep. 2024; 25(8):3601-3626.
PMID: 38956225
PMC: 11315911.
DOI: 10.1038/s44319-024-00191-w.
Krakow E, Brault M, Summers C, Cunningham T, Biernacki M, Black R
Blood. 2024; 144(10):1069-1082.
PMID: 38683966
PMC: 11406181.
DOI: 10.1182/blood.2024024105.
Ma S, Ming Y, Wu J, Cui G
Cell Mol Immunol. 2024; 21(5):419-435.
PMID: 38565887
PMC: 11061161.
DOI: 10.1038/s41423-024-01148-8.
Harnessing the Power of IL-7 to Boost T Cell Immunity in Experimental and Clinical Immunotherapies.
Park J, Lee S, Choi D, Lee C, Sung Y
Immune Netw. 2024; 24(1):e9.
PMID: 38455462
PMC: 10917577.
DOI: 10.4110/in.2024.24.e9.
Altered IL-7 signaling in CD4+ T cells from patients with visceral leishmaniasis.
Kumar S, Bhushan Chauhan S, Upadhyay S, Singh S, Verma V, Kumar R
PLoS Negl Trop Dis. 2024; 18(2):e0011960.
PMID: 38408097
PMC: 10919868.
DOI: 10.1371/journal.pntd.0011960.
Dexamethasone potentiates chimeric antigen receptor T cell persistence and function by enhancing IL-7Rα expression.
Munoz A, Urak R, Taus E, Hsieh H, Awuah D, Vyas V
Mol Ther. 2023; 32(2):527-539.
PMID: 38140726
PMC: 10861975.
DOI: 10.1016/j.ymthe.2023.12.017.
Molecular Mechanisms Underpinning Immunometabolic Reprogramming: How the Wind Changes during Cancer Progression.
Flati I, Di Vito Nolfi M, DallAglio F, Vecchiotti D, Verzella D, Alesse E
Genes (Basel). 2023; 14(10).
PMID: 37895302
PMC: 10606647.
DOI: 10.3390/genes14101953.
Innate and Adaptive Immunity-Related Markers as Predictors of the Short-Term Progression of Subclinical Atherosclerosis in Middle-Aged Patients.
Genkel V, Dolgushin I, Savochkina A, Nikushkina K, Baturina I, Minasova A
Int J Mol Sci. 2023; 24(15).
PMID: 37569579
PMC: 10419170.
DOI: 10.3390/ijms241512205.
The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.
Wang C, Kong L, Kim S, Lee S, Oh S, Jo S
Int J Mol Sci. 2022; 23(18).
PMID: 36142322
PMC: 9499417.
DOI: 10.3390/ijms231810412.
Association between aqueous humor cytokines and postoperative corneal endothelial cell loss after Descemet stripping automated endothelial keratoplasty.
Okabe T, Kobayashi W, Hariya T, Yokokura S, Nakazawa T
PLoS One. 2021; 16(12):e0260963.
PMID: 34914797
PMC: 8675763.
DOI: 10.1371/journal.pone.0260963.
B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T, Miki Y, Suzuki M, Kondoh O, Saito-Koyama R, Ono K
Cancer Med. 2021; 11(2):479-491.
PMID: 34907653
PMC: 8729051.
DOI: 10.1002/cam4.4444.
Functional and metabolic fitness of human CD4 T lymphocytes during metabolic stress.
Holthaus L, Sharma V, Brandt D, Ziegler A, Jastroch M, Bonifacio E
Life Sci Alliance. 2021; 4(12).
PMID: 34580176
PMC: 8500231.
DOI: 10.26508/lsa.202101013.
STAT1 maintains naïve CD8 T cell quiescence by suppressing the type I IFN-STAT4-mTORC1 signaling axis.
Kye Y, Lee G, Lee S, Ju Y, Kim H, Yun C
Sci Adv. 2021; 7(36):eabg8764.
PMID: 34516905
PMC: 8442933.
DOI: 10.1126/sciadv.abg8764.
Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.
Bell M, Gottschalk S
Front Immunol. 2021; 12:684642.
PMID: 34177932
PMC: 8220823.
DOI: 10.3389/fimmu.2021.684642.
Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)-T Cells.
Rad S M A, Halpin J, Mollaei M, Smith Bell S, Hirankarn N, McLellan A
Cancers (Basel). 2021; 13(6).
PMID: 33799768
PMC: 8002030.
DOI: 10.3390/cancers13061229.
Interleukin (IL)-7 Signaling in the Tumor Microenvironment.
Bednarz-Misa I, Bromke M, Krzystek-Korpacka M
Adv Exp Med Biol. 2021; 1290:9-49.
PMID: 33559853
DOI: 10.1007/978-3-030-55617-4_2.
CD8 and CD4 T Cell Populations in Human Kidneys.
van der Putten C, Remmerswaal E, Terpstra M, van der Bom N, Kers J, Ten Berge I
Cells. 2021; 10(2).
PMID: 33535505
PMC: 7912772.
DOI: 10.3390/cells10020288.
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7.
Kim J, Lee K, Lee S
BMB Rep. 2021; 54(1):21-30.
PMID: 33407991
PMC: 7851446.